Literature DB >> 7635954

Two receptor systems are involved in the plasma clearance of tissue-type plasminogen activator (t-PA) in vivo.

M Narita1, G Bu, J Herz, A L Schwartz.   

Abstract

Tissue-type plasminogen activator (t-PA) is a serine protease, catalyzing the initial step in the fibrinolytic process. Intravenously administered t-PA is rapidly cleared from the circulation by the liver. Two distinct clearance mechanisms, which are mediated by the low density lipoprotein receptor-related protein (LRP) on liver parenchymal cells and by the mannose receptor on liver endothelial cells, have been described. Using competitors and inhibitors of the receptors, we investigated the role of LRP and carbohydrate receptors in t-PA clearance in vivo. To inhibit LRP, the 39-kD protein, which is a potent inhibitor of LRP activity, was overexpressed in the liver of mice using an adenoviral gene transfer technique. Expression of the 39-kD protein resulted in a sustained plasma concentration and an increase in the plasma half-life of 125I-t-PA from less than 1 min to 4-5 min. Blockade of the mannose receptor by intravenous administration of ovalbumin also prolonged the plasma half-life of 125I-t-PA to 3-4 min. The same degree of inhibition of t-PA clearance was also observed after administration of an inhibitor of the fucose receptor, fucosyl-BSA. However, under the conditions established for the complete blockade of the mannose receptor, no additional inhibition of t-PA clearance was observed using fucosyl-BSA, suggesting little or no role for the fucose receptor in the clearance of t-PA. Furthermore, a dramatic increase of the plasma half-life of 125I-t-PA (>> 20 min) was observed in mice overexpressing 39-kD protein and administered ovalbumin +/- fucosyl-BSA. Our results clearly demonstrate that two independent receptor systems, LRP and the mannose receptor, are involved in the hepatic clearance of t-PA.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7635954      PMCID: PMC185308          DOI: 10.1172/JCI118105

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  23 in total

1.  Statistical estimations in pharmacokinetics.

Authors:  H G Boxenbaum; S Riegelman; R M Elashoff
Journal:  J Pharmacokinet Biopharm       Date:  1974-04

Review 2.  Cellular receptors for the plasminogen activators.

Authors:  G Bu; I Warshawsky; A L Schwartz
Journal:  Blood       Date:  1994-06-15       Impact factor: 22.113

3.  Tissue-type plasminogen activator: a role for O-linked fucose.

Authors:  J U Baenziger
Journal:  J Clin Invest       Date:  1994-02       Impact factor: 14.808

4.  Identification of domains on the 39-kDa protein that inhibit the binding of ligands to the low density lipoprotein receptor-related protein.

Authors:  I Warshawsky; G Bu; A L Schwartz
Journal:  J Biol Chem       Date:  1993-10-15       Impact factor: 5.157

5.  Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice.

Authors:  J Herz; R D Gerard
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

6.  39-kD protein inhibits tissue-type plasminogen activator clearance in vivo.

Authors:  I Warshawsky; G Bu; A L Schwartz
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

7.  Inhibition of hepatic chylomicron remnant uptake by gene transfer of a receptor antagonist.

Authors:  T E Willnow; Z Sheng; S Ishibashi; J Herz
Journal:  Science       Date:  1994-06-03       Impact factor: 47.728

8.  Low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor is an hepatic receptor for tissue-type plasminogen activator.

Authors:  G Bu; S Williams; D K Strickland; A L Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

9.  alpha-Fucose-mediated binding and degradation of tissue-type plasminogen activator by HepG2 cells.

Authors:  K A Hajjar; C M Reynolds
Journal:  J Clin Invest       Date:  1994-02       Impact factor: 14.808

10.  Low density lipoprotein receptor-related protein is necessary for the internalization of both tissue-type plasminogen activator-inhibitor complexes and free tissue-type plasminogen activator.

Authors:  K Orth; T Willnow; J Herz; M J Gething; J Sambrook
Journal:  J Biol Chem       Date:  1994-08-19       Impact factor: 5.157

View more
  12 in total

1.  RAP, a specialized chaperone, prevents ligand-induced ER retention and degradation of LDL receptor-related endocytic receptors.

Authors:  T E Willnow; A Rohlmann; J Horton; H Otani; J R Braun; R E Hammer; J Herz
Journal:  EMBO J       Date:  1996-06-03       Impact factor: 11.598

2.  Recombinant T cell receptor ligand treatment improves neurological outcome in the presence of tissue plasminogen activator in experimental ischemic stroke.

Authors:  Wenbin Zhu; Nicole L Libal; Amanda Casper; Sheetal Bodhankar; Halina Offner; Nabil J Alkayed
Journal:  Transl Stroke Res       Date:  2014-06-24       Impact factor: 6.829

Review 3.  Drug delivery by red blood cells: vascular carriers designed by mother nature.

Authors:  Vladimir R Muzykantov
Journal:  Expert Opin Drug Deliv       Date:  2010-04       Impact factor: 6.648

Review 4.  Red blood cells: The metamorphosis of a neglected carrier into the natural mothership for artificial nanocarriers.

Authors:  Patrick M Glassman; Elizabeth D Hood; Laura T Ferguson; Zongmin Zhao; Don L Siegel; Samir Mitragotri; Jacob S Brenner; Vladimir R Muzykantov
Journal:  Adv Drug Deliv Rev       Date:  2021-09-29       Impact factor: 15.470

5.  Targeting of a mutant plasminogen activator to circulating red blood cells for prophylactic fibrinolysis.

Authors:  Sergei Zaitsev; Sergei Zaitzev; Dirk Spitzer; Juan-Carlos Murciano; Bi-Sen Ding; Samira Tliba; M Anna Kowalska; Khalil Bdeir; Alice Kuo; Victoria Stepanova; John P Atkinson; Mortimer Poncz; Douglas B Cines; Vladimir R Muzykantov
Journal:  J Pharmacol Exp Ther       Date:  2009-12-01       Impact factor: 4.030

6.  Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype.

Authors:  Kara N Maxwell; Jan L Breslow
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-26       Impact factor: 11.205

7.  Modulation of circulatory residence of recombinant acetylcholinesterase through biochemical or genetic manipulation of sialylation levels.

Authors:  T Chitlaru; C Kronman; M Zeevi; M Kam; A Harel; A Ordentlich; B Velan; A Shafferman
Journal:  Biochem J       Date:  1998-12-15       Impact factor: 3.857

Review 8.  Delivery of drugs bound to erythrocytes: new avenues for an old intravascular carrier.

Authors:  Carlos H Villa; Daniel C Pan; Sergei Zaitsev; Douglas B Cines; Donald L Siegel; Vladimir R Muzykantov
Journal:  Ther Deliv       Date:  2015-07

9.  Erythrocyte-bound tissue plasminogen activator is neuroprotective in experimental traumatic brain injury.

Authors:  Sherman C Stein; Kumkum Ganguly; Caitlin M Belfield; Xiangsheng Xu; Edward W Swanson; Xiao-Han Chen; Kevin D Browne; Victoria E Johnson; Douglas H Smith; David G LeBold; Douglas B Cines; Vladimir R Muzykantov; Vladimir R Muzykhantov
Journal:  J Neurotrauma       Date:  2009-09       Impact factor: 5.269

10.  RiboTag analysis of actively translated mRNAs in Sertoli and Leydig cells in vivo.

Authors:  Elisenda Sanz; Ryan Evanoff; Albert Quintana; Elizabeth Evans; Jeremy A Miller; Chemyong Ko; Paul S Amieux; Michael D Griswold; G Stanley McKnight
Journal:  PLoS One       Date:  2013-06-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.